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Abstract 
Background: End-of-life (EOL) care imposes heavy economic burdens on patients and 
health insurers. Little is known about the association between the types of EOL care and 
health care costs for cancer patients across various providers.  
Objective: To explore the association of health care expenditures with benchmarking 
indicators of aggressive versus palliative care among terminally ill cancer patients, from the 
perspective of health insurers. 
Design: Cross-sectional retrospective study using health insurance claims data. 
Setting/Participants: Cancer patients who had died in Kyoto prefecture, Japan, between 
April 2009 and May 2010.  
Main Outcome Measure: Claims data were analyzed using multilevel generalized linear 
models to examine whether aggressive care and palliative care were associated with 
expenditures during the last 3 months of life, after adjusting for patient characteristics, 
hospital characteristics, and other non-indicator procedures. 
Results: We analyzed 3,143 decedents from 54 hospitals. Median expenditure per patient 
during the last 3 months was US$13,030. Higher expenditures were associated with the 
aggressive care indicators of higher mortality at acute-care hospitals and use of chemotherapy 
in the last month of life, as well as with the palliative care indicators of increased hospice care 
and opioid use in the last 3 months of life. However, increased physician home care in the last 
3 months was associated with lower expenditure. 
Conclusions: Indicators of both aggressive and palliative EOL care were associated with 
higher health care expenditures. These results may support the coherent development of 
measures to optimize aggressive care and reduce the financial burdens of terminal cancer 
care. 
 
Key words: quality measurement; neoplasms; economics; administrative data; intensive care; 
palliative care.
Introduction 
The populations of many developed nations are aging rapidly, accompanied by dramatic 
increases in national health care costs. End-of-life (EOL) care imposes a substantial economic 
burden on patients and health insurers, and the EOL component of health care costs are 
frequently targeted in efforts to control overall costs [1,2]. Although numerous reports have 
been published on health care costs and the utilization of health care services in terminally ill 
patients, these tend to focus on all-cause mortality [1-8]. Among the leading causes of death, 
cancer has one of the highest fatality rates in many countries, including Japan [9]. Currently, 
there are not many studies that have explored EOL health care expenditures associated with 
cancer patients irrespective of cancer type [10-19]. Little is known about the determinants of 
EOL health care expenditures incurred for treating terminally ill cancer patients in various 
health care settings. Therefore, comprehensive studies that integrate various settings (e.g., 
hospitals, intensive care units [ICU], hospices, and patient homes) are required. 
The quality of EOL care has also been the focus of numerous studies. Quality indicators 
based on procedures for terminal cancer care have been developed for analyses using 
administrative data [20-25]. Although intensive treatments may be employed during EOL care, 
aggressive procedures do not necessarily correlate with better quality of life (QOL) for the 
patients [26-29]. Therefore, replacing certain aspects of aggressive care in favor of increased 
palliative care may improve QOL and reduce the use of health care resources [2, 26]. 
 
Unfortunately, little is known about the relationship between aggressive/palliative care and 
health care expenditures at the EOL. 
In contrast to the US and Europe, palliative and hospice care are not well-established in 
Japan and other Asian countries [30]. Approximately 80% of terminally ill patients in Japan 
die in hospitals, while only 3% of deaths occur at hospices [31]. 
Understanding the associations between health care expenditures and the provision of 
aggressive/palliative care at the EOL can help clinical leaders and policy-makers to optimize 
EOL care and reduce expenditures. In this study, we aimed to explore the association of EOL 
health care expenditures with aggressive versus palliative care indicators from the perspective 
of health insurers, based on a comprehensive analysis of administrative claims data of 
terminally ill cancer patients in Japan. 
 
Methods 
Study design and data source 
We conducted a cross-sectional retrospective analysis using health insurance claims data from 
Kyoto prefecture, Japan. The data source comprised reimbursement claims electronically 
submitted from health care providers to National Health Insurance (NHI) and Long Life 
Medical Care System (LLMCS), two major insurance payers in Japan. NHI provides 
insurance coverage for individuals not working in companies (e.g., farmers, the self-employed, 
 
retirees, the unemployed, part-time workers, and their families). LLMCS provides coverage 
for individuals aged 75 years or older, as well as for disabled individuals aged 65–74 years. 
Both the NHI and LLMCS pay for the majority of medical services and medications for 
beneficiaries, including palliative care services (e.g., hospice care, physician home care, and 
opioid use).  
 
Study population 
A total of 3,323 cancer patients who had died between April 2009 and May 2010 with 
available claims records for at least 3 months prior to death were included in this study. 
Cancer was defined according to the International Classification of Diseases, 10th Revision 
(ICD-10, codes Cxx.x). We excluded from analysis patients who did not receive EOL care at 
hospitals or hospices during their last 3 month of life (n = 23) and those who received EOL 
care at hospitals with fewer than 10 terminally ill cancer patients (n = 157). There were 3,143 
patients included in the final analysis.  
 
Response variable 
The response variable used in this study was direct health care expenditures (including 
copayment and health insurance coverage) for each decedent during the last 3 months of life 
across various health care settings (inpatient, outpatient, hospital, hospice, office, home care, 
 
and pharmacy). We focused on the last 3 months of life because it has been previously stated 
that terminally ill patients should ideally receive hospice care for 3 months before death [32]. 
 
Explanatory variables 
Data on patient characteristics were obtained using claims data corresponding to the last 3 
months of life. Types of cancer were classified into the following categories based on ICD-10 
codes (Table 1): lung, stomach, colorectum, liver, pancreas, biliary tract, blood (leukemia, 
Hodgkin's disease, and non-Hodgkin's lymphoma), prostate, breast, and others. A comorbidity 
score was calculated according to ICD-10 coding algorithms for the Charlson Comorbidity 
Index (excluding cancer-related diseases) [33]. 
We used the recommended benchmark measures for terminal cancer care developed 
and validated by Earle et al. [20-25] to identify aggressive and palliative procedures from 
administrative data. These measures were: (a) dying at acute-care hospitals (aggressive care), 
(b) receiving chemotherapy using cytotoxic agents or molecular-targeted therapies during the 
last month of life (aggressive care), (c) admission to ICUs or receiving life-sustaining 
treatments (cardiopulmonary resuscitation, intubation, or mechanical ventilation) during the 
last month of life (aggressive care), and (d) admission to institutional hospices or palliative 
care units during the last 3 months of life (palliative care). Additionally, the following 
procedures during the last 3 months of life were included as indicators of palliative care: (e) 
 
palliative team consultation using multidisciplinary approaches [20, 24, 25], (f) opioid use 
[23], and (g) home care provided by family practitioners [24, 25]. The following 
non-indicator procedures were identified as potential confounding factors: total parenteral 
nutrition, dialysis, blood transfusion, rehabilitation, surgery, and radiotherapy during the last 3 
months of life. Also included as potential confounding factors were chemotherapy, ICU 
admission, or life-sustaining treatments during the last 2 months prior to the month in which 
the patient died. 
Treatment hospitals during the last 3 months of life were identified for each patient in 
the following order: the first acute-care hospital that provided inpatient care, followed by the 
first acute-care hospital that provided outpatient care, and finally the first hospice. Hospital 
characteristics included hospitals teaching status, urban/rural location (urban referring to any 
location within the prefectural capital city and rural referring to anything outside the city), and 
ownership (governmental, public, or private). 
 
Statistical analysis 
Multilevel regression models were developed for patients clustered in hospitals, with a 
random intercept at level 2 used to handle data comprising patients within a given hospital. 
Patient characteristics, the various indicator procedures, and non-indicator procedures were 
used as explanatory variables at level 1; hospital characteristics were added at level 2. 
 
Because the distribution of health care cost data is typically skewed to the right, generalized 
linear models (GLM) with a gamma distribution and log link function were used to evaluate 
health care expenditures [34]. Gamma regression models are multiplicative. Using an 
approach outlined in a previous study [3], the exponentiated coefficients of each explanatory 
variable were interpreted as rate ratios (RRs), with an RR of 1 indicating no association of 
that explanatory variable with increased or decreased values of the response variable. All 
explanatory variables used in the multilevel GLM were calculated as categorical variables. 
We performed three sets of multivariable analyses. In the first model (Model 1), patient 
characteristics and hospital characteristics were included in analysis. In the second model 
(Model 2), non-indicator procedures were entered in addition to the variables included in 
Model 1. In the third model (Model 3), aggressive/palliative indicators of EOL care were 
entered in addition to the variables included in Model 2. Model 3 was used to assess the 
association between aggressive/palliative indicators of procedures and health care 
expenditures at EOL, while controlling for patient characteristics, hospital characteristics, and 
other non-indicator procedures. The goodness of fit of each model was compared using the 
Akaike Information Criterion (AIC), where smaller values denote a better fit. 
We used IBM SPSS version 19 (SPSS Inc., Chicago, IL) for data manipulation and 
SAS version 9.2 (SAS Institute Inc., Cary, NC) for analyses. A two-sided test was used and P 
< 0.05 was considered significant. All health care expenditures were reported in US dollars, 
 
using the 2011 purchasing power parity rate for Japanese yen to US dollars (¥107 = $1) from 




The present study involved 3,143 decedents from 54 hospitals. Median health care 
expenditure per patient during the last 3 months of life was $13,030 (interquartile range, 
$8,120–$18,970).  
Table 2 shows the patient and hospital characteristics of the study sample. 
Hospital-level data for each patient is included and expressed as the number of patients in 
each category. The majority of decedents were in the 75–79 years age group, with a higher 
proportion of men. The most common type of cancer was lung cancer, followed by gastric 
cancer. Our findings showed that patients died predominantly in acute-care hospitals (89%), 
and that 7% of patients underwent chemotherapy during the last month of life. Nine percent of 
patients were admitted to ICUs or received life-sustaining treatments during the last month; 
6% and 3% used hospice services and received palliative team consultation, respectively. 
 
Patient and hospital characteristics and health care expenditure 
Table 3 shows RR estimates for the multivariable regression models used in this study. Model 
 
1 evaluated the association between patient and hospital characteristics and health care 
expenditures during the last 3 months of life. After adjusting for other patient characteristics, 
age was found to be significantly associated with health care expenditure. Also, when 
compared with lung cancer patients, the health care expenditures for EOL care were 
significantly lower in patients with liver cancer and higher for those with blood or prostate 
cancer. Patients from hospitals in urban areas incurred higher expenditure compared with 
those in rural areas. 
Non-indicator EOL procedures were entered into Model 2 in addition to the variables 
included in Model 1. For non-indicator procedures, results are presented as an RR for patients 
who received a non-indicator procedure when compared with those who did not receive it 
(serving as the referent group), after adjusting for patient and hospital characteristics and 
other non-indicator procedures. All procedures were found to be significantly associated with 
higher expenditures. Teaching, public, and private hospitals were associated with lower 
expenditures than non-teaching and governmental hospitals. 
 
Aggressive versus palliative care and health care expenditure 
Model 3 was used to assess the association between aggressive/palliative EOL care and health 
care expenditure during the last 3 months of life (Table 3). Results for aggressive/palliative 
care in Model 3 are presented in the same way as non-indicator procedures in Model 2, with 
 
patients who did not receive the procedures used as the referent groups. Similar to Models 1 
and 2, factors showing significant association with health care expenditures included age, 
certain cancer types, Charlson Comorbidity Index, non-indicator procedures, and certain 
hospital characteristics. Also, significant associations were found between aggressive 
treatments and higher expenditures. Patients who died in acute-care hospitals were associated 
with higher expenditure when compared with those who died at home or at a hospice (RR: 
1.32; 95% confidence interval [CI] 1.21–1.44). Patients who underwent chemotherapy during 
the last month of life were associated with higher expenditure when compared with those who 
did not (RR: 1.25; 95% CI 1.17–1.34). ICU care or life-sustaining treatments during the last 
month were not associated with health care expenditures for insurers. 
Our results showed that specific palliative procedures were significantly associated with 
either an increase or decrease in health care expenditures. The RRs (95% CI) of hospice 
services, opioid use, and physician home care in Model 3 were 2.31 (2.07–2.59), 1.07 
(1.03–1.11), and 0.90 (0.84–0.98), respectively. We found no significant association between 
palliative team consultation and health care expenditure. The AIC indicated that Model 3 
fitted the data better than Models 1 and 2. 
 
Discussion 
This study explored the association of health care expenditures with aggressive versus 
 
palliative care for terminally ill cancer patients across various health care settings. Our 
findings were obtained from a single dataset, which showed that both aggressive and 
palliative procedures were differentially associated with variations in expenditures. The 
novelty of this study lies in the identification of specific terminal procedures that are 
significantly associated with EOL expenditures based on a comprehensive analysis of direct 
health care expenditures for terminally ill cancer patients. 
Our study showed that aggressive care was generally associated with higher health care 
expenditures. On the other hand, physician home care (regarded as palliative care) was 
associated with reduced expenditures. These results are similar to those of previous studies 
attributing cost differences to a reduction in acute-care services provided during EOL [4, 5, 
10]. Other studies have shown that physician home care is associated with good QOL and 
better satisfaction at EOL [4, 27, 28]. Our findings corroborate these reported results, and may 
indicate that measures to improve cost savings and QOL can involve the control of aggressive 
care and promotion of home care for terminal cancer patients, although this requires further 
studies to determine if there is a causal relationship between these factors [2, 26]. 
To promote cost savings and reduce aggressive care at the EOL, several fundamental 
problems must first be addressed. First, physicians are not always accurate in predicting 
actual time to death [35]. Second, there are no gold standards for the appropriate time to stop 
aggressive therapy. Third, patients are rarely prepared for death, which may be exacerbated in 
 
many Eastern countries due to taboos against open discussions concerning death [30]. 
Advance directives documenting patient preferences for the use or avoidance of 
life-sustaining treatments or procedures have been shown to reduce health care expenditures 
[1, 11]. New policies are required to encourage people to consider more preferable ways to 
die, to promote physician and medical student education about EOL care, and to expand 
palliative care programs in hospitals. 
Japan is promoting the policy of home death in anticipation of an increase of decedents 
incurring huge health care expenditures at the EOL [36]. The promotion of physician home 
care and eventual death at home may be a possible means to reduce the surge in EOL health 
care expenditures that can be expected from the rising number of decedents in aging Japan. 
This policy may take the form of improved systems and incentives for physicians to provide 
home care, as well as engaging patient interest groups to improve acceptance of death at 
home. 
We demonstrated that hospice service and opioid use, which were used as palliative 
care indicators, were associated with increased health care expenditures. With regard to 
whether hospice services generate more cost or enable cost savings, our findings differ from 
those of previous studies from other countries, which have indicated that hospice services 
reduce overall health care costs [6-8, 12, 13]. This inconsistency may be due to the higher 
fees for hospice care when compared with acute care in Japan. 
 
 Limitations 
Our study has several limitations that should be noted. Firstly, because a claims database was 
used in this study, we were unable to include information regarding other health outcomes 
such as QOL, patient satisfaction, patient preferences, or clinical details which might further 
explain cost-related differences. This may lead to possible confounding of the results, but is 
an intrinsic limitation of administrative data-based studies. Secondly, this study is a 
retrospective observational analysis, and as such is unable to determine causal relationships. 
Finally, although Japan has a long-term care (LTC) insurance system which supports the 
elderly living at home or in nursing care facilities, LTC insurance claims data were not 
available for analysis. This insurance program provides payment for in-home care and facility 
services, including nursing care and rehabilitation. Patients who receive physician home care 
may use these services covered by LTC insurance. Hence, further studies are needed to 
incorporate data from both health and LTC insurance claims databases. 
With regard to home care, an association between having nearby family and lower 
health care costs has been reported, which may indicate that relatives can act as caregivers to 
help patients avoid undesired hospitalizations [3]. However, policies that promote home care 
may lead to the shifting of costs from health insurers to LTC insurers, patients, or relatives in 
the form of having to provide more formal care, loss in productivity, or additional payments 
 
for hired caregivers. Further investigations from the societal perspective are warranted in 
order to better inform the policymaking process. 
 
Conclusions 
In this study, we evaluated the association of health care expenditures with aggressive versus 
palliative care for terminally ill cancer patients in Japan. Our findings show that certain 
modes of both aggressive and palliative care during the last few months of life were 
associated with increased health care expenditures independent of other factors, and that 
physician home care was associated with reduced expenditures. The findings in this study 
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Colorectum C18.x, C19.x, C20.x 
Liver C22.x 
Pancreas C25.x 
Biliary tract C23.x, C24.x 
Blood C81.x–C85.x, C91.x–C95.x 
Prostate C61.x 
Breast C50.x 
Other C00.x–C15.x, C17.x, C21.x, C26.x, C30.x–C33.x, C37.x–C41.x, C43.x–C49.x, 
C51.x–C58.x, C60.x, C62.x–C80.x, C88.x, C90.x, C96.x, C97.x 
ICD-10, International Classification of Diseases, 10th Revision. 
 
Table 2. Study population characteristics and performance of aggressive and palliative care indicators 
No. of patients 3143 
Patient characteristics 
 
Women 1249 (40) 
Age, y 
 
<65 383 (12) 
65–69 388 (12) 
70–74 452 (14) 
75–79 698 (22) 
80–84 631 (20) 
≥85 591 (19) 
Cancer type 
 
Lung 622 (20) 
Stomach 444 (14) 
Colorectum 367 (12) 
Liver 302 (10) 
Pancreas 265 (8) 
Biliary tract 151 (5) 
Blood 180 (6) 
Prostate 91 (3) 
Breast 80 (3) 
Other 641 (20) 
Charlson Comorbidity Index 
 
0–1 1197 (38) 
2 642 (20) 
3 434 (14) 
≥4 870 (28) 
 




Death at acute-care hospitals 2811 (89) 
Chemotherapya 234 (7) 
ICU care or life-sustaining treatmentsa 284 (9) 
Palliative care 
 
Hospice careb 202 (6) 
Palliative team consultationb 86 (3) 
Opioid useb 1697 (54) 
Physician home careb 172 (5) 
Non-indicator procedures  
Total parenteral nutritionb 1126 (36) 
Dialysisb 48 (2) 
Blood transfusionb 871 (28) 
Rehabilitationb 686 (22) 
Surgeryb 104 (3) 
Radiotherapyb 216 (7) 
Chemotherapyc 1196 (38) 
ICU care or life-sustaining treatmentsc 86 (3) 
Hospital characteristics 
 
Teaching hospital 2075 (66) 
Urban location 2029 (65) 
Ownership 
 
Governmental 1031 (33) 
Public 642 (20) 
Private 1470 (47) 
Values are expressed as number of patients (column percentage). Because of rounding, percentages 
may not add up to 100%. Patients who had undergone more than one procedure are accordingly 
classified into more than one category for procedures. a Identified during the last month of life. b Identified 
during the last 3 months. c Identified during the last 2 months prior to the month in which the patient died. 
ICU, intensive care unit. 
 
Table 3. The association between health care expenditures during the last 3 months of life and patient 
characteristics, hospital characteristics, non-indicator procedures, and aggressive/palliative care 
 














Patient characteristics       
Women 0.99 (0.95–1.04) 0.81 1.00 (0.96–1.04) 0.88 1.00 (0.96–1.03) 0.82 
Agea       
65–69 0.91 (0.83–0.99) 0.02 0.91 (0.84–0.98) 0.01 0.93 (0.87–1.00) 0.05 
70–74 0.93 (0.86–1.02) 0.11 1.00 (0.93–1.08) 0.92 1.02 (0.95–1.09) 0.55 
75–79 0.91 (0.84–0.98) 0.01 0.95 (0.89–1.02) 0.13 0.97 (0.91–1.03) 0.33 
80–84 0.80 (0.74–0.87) <0.001 0.91 (0.85–0.98) 0.009 0.94 (0.88–1.01) 0.08 
≥85 0.71 (0.66–0.77) <0.001 0.85 (0.79–0.92) <0.001 0.91 (0.84–0.97) 0.007 
Cancer typeb 
      
Stomach 1.05 (0.98–1.13) 0.19 0.91 (0.85–0.97) 0.006 0.94 (0.88–1.00) 0.04 
Colorectum 1.08 (1.00–1.17) 0.07 0.98 (0.91–1.05) 0.53 0.99 (0.93–1.06) 0.79 
Liver 0.82 (0.75–0.89) <0.001 0.91 (0.84–0.98) 0.02 0.95 (0.88–1.02) 0.14 
Pancreas 0.95 (0.87–1.04) 0.25 0.96 (0.89–1.04) 0.34 0.99 (0.92–1.06) 0.68 
Biliary tract 1.05 (0.94–1.17) 0.35 1.03 (0.94–1.13) 0.56 1.08 (0.98–1.18) 0.11 
Blood 1.81 (1.64–2.00) <0.001 1.38 (1.26–1.51) <0.001 1.32 (1.21–1.45) <0.001 
Prostate 1.16 (1.01–1.33) 0.03 1.02 (0.91–1.15) 0.75 0.99 (0.88–1.10) 0.79 
Breast 1.07 (0.92–1.24) 0.37 1.04 (0.92–1.19) 0.53 1.04 (0.92–1.18) 0.49 
Other 1.08 (1.01–1.16) 0.02 0.97 (0.92–1.03) 0.40 0.97 (0.91–1.02) 0.23 
Charlson Comorbidity Indexc 
      
2 0.99 (0.94–1.05) 0.86 0.95 (0.90–1.00) 0.04 0.98 (0.93–1.03) 0.37 
3 1.04 (0.98–1.12) 0.20 0.98 (0.93–1.04) 0.58 0.99 (0.94–1.05) 0.85 
≥4 1.15 (1.08–1.21) <0.001 1.00 (0.95–1.05) 0.91 1.06 (1.01–1.11) 0.01 
 
Table 3 continued 














Procedures       
Aggressive cared 
  
    
Death at acute-care hospitalse     1.32 (1.21–1.44) <0.001 
Chemotherapy*     1.25 (1.17–1.34) <0.001 
ICU care or life-sustaining 
treatments* 
  
  1.01 (0.95–1.08) 0.71 
Palliative cared       
Hospice care†     2.31 (2.07–2.59) <0.001 
Palliative team consultation†     0.98 (0.87–1.09) 0.66 
Opioid use†     1.07 (1.03–1.11) <0.001 
Physician home care†     0.90 (0.84–0.98) 0.01 
Non-indicator proceduresd       
Total parenteral nutrition†   1.33 (1.27–1.38) <0.001 1.39 (1.33–1.44) <0.001 
Dialysis†   1.47 (1.26–1.71) <0.001 1.50 (1.29–1.73) <0.001 
Blood transfusion†   1.33 (1.27–1.39) <0.001 1.35 (1.29–1.41) <0.001 
Rehabilitation†   1.32 (1.26–1.39) <0.001 1.35 (1.29–1.41) <0.001 
Surgery†   1.32 (1.19–1.46) <0.001 1.31 (1.18–1.45) <0.001 
Radiotherapy†   1.32 (1.23–1.43) <0.001 1.34 (1.25–1.44) <0.001 
Chemotherapy‡   1.14 (1.09–1.18) <0.001 1.15 (1.11–1.20) <0.001 
ICU care or life-sustaining 
treatments‡ 
  1.55 (1.38–1.75) <0.001 1.54 (1.37–1.73) <0.001 
Hospital characteristics       
Teaching hospitalf 0.99 (0.94–1.04) 0.69 0.92 (0.88–0.97) 0.001 0.97 (0.93–1.01) 0.18 
Urban locationg 1.31 (1.25–1.37) <0.001 1.30 (1.25–1.36) <0.001 1.22 (1.17–1.27) <0.001 
Ownershiph       
Public 0.94 (0.88–1.00) 0.05 0.93 (0.89–0.99) 0.01 0.93 (0.88–0.98) 0.004 
Private 0.96 (0.91–1.02) 0.16 0.91 (0.87–0.96) <0.001 0.91 (0.86–0.95) <0.001 
Model fit statistics       
Akaike Information Criterion 94455  93513  93216  
*Identified during the last month of life. †Identified during the last 3 months. ‡Identified during the last 2 months 
prior to the month in which the patient died. Referent categories: a <65 years, b lung, c 0–1, d non-use of each of the 
procedures unless otherwise indicated, e home or hospice, f non-teaching, g rural, h governmental. 
CI, confidence interval; ICU, intensive care unit. 
 
 
